Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Sales (2016 - 2025)

Historic Return on Sales for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to 0.27%.

  • Adma Biologics' Return on Sales fell 300.0% to 0.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.43%, marking a year-over-year increase of 2500.0%. This contributed to the annual value of 0.46% for FY2024, which is 5700.0% up from last year.
  • As of Q3 2025, Adma Biologics' Return on Sales stood at 0.27%, which was down 300.0% from 0.28% recorded in Q2 2025.
  • Adma Biologics' Return on Sales' 5-year high stood at 0.95% during Q4 2024, with a 5-year trough of 1.14% in Q1 2021.
  • In the last 5 years, Adma Biologics' Return on Sales had a median value of 0.12% in 2023 and averaged 0.14%.
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 15300bps in 2021, then crashed by -300bps in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Return on Sales stood at 0.3% in 2021, then grew by 21bps to 0.24% in 2022, then dropped by -1bps to 0.24% in 2023, then surged by 499bps to 0.95% in 2024, then plummeted by -71bps to 0.27% in 2025.
  • Its Return on Sales was 0.27% in Q3 2025, compared to 0.28% in Q2 2025 and 0.23% in Q1 2025.